Q-omics provides the consensus-scored MAST1 profile across patient tissues and cancer cell-line models. MAST1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAST1 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, MAST1 RNA expression shows 19,769 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where MAST1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAST1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAST1 survival associations across molecular data types. MAST1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAST1 RNA expression–survival associations across cancer types. High MAST1 expression shows unfavorable associations in KIRC, UCEC and MESO, but favorable associations in LGG, HNSC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAST1 RNA expression.
This table summarizes MAST1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MAST1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAST1 shows higher tumor expression in KIRP, LUAD, HNSC, LUSC, BLCA and UCEC. The KIRP box plot shows higher MAST1 RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with MAST1 in patient tissues and cancer cell lines. In patient samples, MAST1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAST1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
